SEVERANCE AGREEMENTSeverance Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 30th day of November, 2006 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”) and Mitchel Sayare (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”), dated as of November 30, 2006 (the “Effective Date”), is made by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and John M. Lambert, Ph.D. (“Executive”). This Agreement is intended to confirm the understanding and set forth the agreement between the Company and Executive with respect to Executive’s employment by the Company. In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and the Executive hereby agree as follows:
PROPRIETARY INFORMATION, INVENTIONS, AND COMPETITION AGREEMENTProprietary Information, Inventions, and Competition Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT, dated this 30th day of November 2006, by and between ImmunoGen, Inc., a Massachusetts corporation having its principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (the “Company”), and Mitchel Sayare, an individual residing at 2 Avery Street, Suite 27c, Boston, MA 02111 (“Employee”).
PROPRIETARY INFORMATION, INVENTIONS, AND COMPETITION AGREEMENTInventions, and Competition Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT, dated this 30th day of November 2006, by and between ImmunoGen, Inc., a Massachusetts corporation having its principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (the “Company”), and John M. Lambert, Ph.D., an individual residing at 19 Chalk Street, Cambridge, MA 02139 (“Employee”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Delaware
This Option and License Agreement (this “Agreement”) is made effective as of December 21, 2006 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation with a principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U.S. LLC, a limited liability company organized and existing under the laws of Delaware with offices at 1041 Rt. 202-206, Bridgewater, NJ 08807 (“sanofi-aventis”). Each of sanofi-aventis and ImmunoGen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • Delaware
This LICENSE AGREEMENT (this “Agreement”) is entered into as of October 5, 2006, by and between ImmunoGen, Inc., a Massachusetts corporation having a principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U.S. LLC, a limited liability company organized and existing under the laws of Delaware with offices at 1041 Rt.202-206, Bridgewater, NJ 08807 (“sanofi-aventis”). Each of sanofi-aventis and ImmunoGen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • February 8th, 2007 • Immunogen Inc • Pharmaceutical preparations • California
This License Agreement (the “Agreement”) is made effective as of July 22, 2005 (the “Effective Date”) by and between GENENTECH, INC., a Delaware corporation having its principal business office at 1 DNA Way, South San Francisco, California 94080 (“GENENTECH”), and IMMUNOGEN, INC., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (“IMMUNOGEN”). GENENTECH and IMMUNOGEN are each hereafter referred to individually as a “Party” and together as the “Parties”.
